{"paper_id":"62535692-11f8-4443-8112-07d03ad191b7","body_text":"Abstract\nIntroduction: Recent reports consider endometriosis to be an immunological disorder, thus suggesting potential efficacy of immunomodulators for its treatment. The aim of this study was to assess the effects of oral administration of pentoxifylline on endometriosis-like lesions in a heterologous mice model. Study Design: Human endometrial tissue obtained from women (n = 5) undergoing surgery for benign conditions was implanted in nude female mice (n = 30). The animals were distributed into 3 experimental groups receiving: saline 0.1 mL/d (control, group I); pentoxifylline 100 mg/kg/d (group 2), and pentoxifylline 200 mg/kg/d (group 3). After 28 days, the number of implants and the total volume of surgically extracted tissue were recorded. Immunohistochemical analysis was performed to assess the area of endometriosis and vascularization of endometriosis-like lesions. Cytokine levels in peritoneal fluid samples were measured. Results: Macroscopic quantification showed a trend to dose-dependent reduction in the number of the endometriosis-like lesions after 28 days. The volume was significantly reduced in group 3 versus group 2 and controls (399.10 ± 120.68 mm3 vs 276.75 ±94.30 mm3 and 145.33 ± 38.20 mm3, respectively; P = .04). Similarly, the mean area of endometriosis was significantly lower in group 3 (0.12 ± 0.08 mm2) versus group 2 (1.35 ± 0.43 mm2) and control (2.84 ± 0.60 mm2; P = .001). Vascularization and cytokine levels were also reduced posttreatment. Conclusion: Our results suggest that the oral administration of pentoxifylline may be an alternative to current therapies for endometriosis. Nonetheless, further studies are required.\nSimilar content being viewed by others\nReferences\nBurney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–519.\nMahmood TA, Templeton A. Pathophysiology of mild endometriosis: review of literature. Hum Reprod. 1990;5(7):765–784.\nMehedintu C, Plotogea MN, Ionescu S, Antonovici M. Endometriosis still a challenge. J Med Life. 2014;7(3):349–357.\nChapron C, Santulli P, Cabri P. The pain and daily consequences of living with endometriosis: a qualitative online survey of women in China, France and Russia. J Endometr. 2015;7(3):89–94.\nSampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3(2):93–110.43.\nTosti C, Pinzauti S, Santulli P, Chapron C, Petraglia F. Pathogenetic mechanisms of deep infiltrating endometriosis. Reprod Sci. 2015;22(9):1053–1059.\nNothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76(2):223–231.\nLousse JC, Van Langendonckt A, Defrere S, Ramos RG, Colette S, Donnez J. Peritoneal endometriosis is an inflammatory disease. Front Biosci (Elite Ed). 2012;4:23–40.\nOlive DL, Lindheim SR, Pritts EA. New medical treatments for endometriosis. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):319–328.\nLu D, Song H, Li Y, Clarke J, Shi G. Pentoxifylline for endometriosis. Cochrane Database Syst Rev. 2012;1:CD007677.\nCreus M, Fâbregues F, Carmona F, del Pino M, Manau D, Balasch J. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod. 2008;23(8):1910–1916. doi:10.1093/humrep/den167.\nKamencic H, Thiel JA. Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial. J Minim Invasive Gynecol. 2008;15(1):62–66.\nDrugs@FDA: FDA Approved Drug Products [Internet]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018631s0391b1.pdf. Accessed October 2, 2016.\nNisolle M, Casanas-Roux F, Donnez J. Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. Fertil Steril. 2000;74(2):306–312.\nReagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–661.\nDefrère S, Van Langendonckt A, González Ramos R, Jouret M, Mettlen M, Donnez J. Quantification of endometriotic lesions in a murine model by fluorimetric and morphometric analyses. Hum Reprod. 2006;21(3):810–817.\nPotlog-Nahari C, Feldman AL, Stratton P, et al. CD10 immuno-histochemical staining enhances the histological detection of endometriosis. Fertil Steril. 2004;82(1):86–92.\nSong IO, Hong SR, Huh Y, et al. Expression of vimentin and cytokeratin in eutopic and ectopic endometrium of women with adenomyosis and ovarian endometrioma. Am J Reprod Immunol. 1998;40(1):26–31.\nChen H, Luo Q, Liu S, Xiong H, Jiang Q. Rectal mucosal endometriosis primarily misinterpreted as adenocarcinoma: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(5):5902–5907. eCollection 2015.\nBourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006;132(3):501–509.\nRice VM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci. 2002;955:343–352.\nVercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275.\nZupi E, Lazzeri L, Centini G. Endometriosis and pain: postsurgical alternative treatment in patients desiring pregnancy. J Endometr Pelvic Pain Disord. 2015;7(3):95–99.\nNothnick WB. Endometriosis: in search of optimal treatment. Minerva Ginecol. 2010;62(1):17–31.\nSteinleitner A, Lambert H, Suarez M, Serpa N, Roy S. Immunomodulation in the treatment of endometriosis-associated subferti-lity: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model. Fertil Steril. 1991;56(5):975–979.\nSteinleitner A, Lambert H, Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril. 1991;55(1):26–31.\nLv D, Song H, Li Y, Clarke J, Shi G. Pentoxifylline versus medical therapies for subfertile women with endometriosis. Cochrane Database Syst Rev. 2009;(3):CD007677.\nAlborzi S, Ghotbi S, Parsanezhad ME, Dehbashi S, Alborzi S, Alborzi M. Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study. J Minim Invasive Gynecol. 2007;14(1):54–58.\nBalasch J, Creus M, Fábregues F, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod. 1997;12(9):2046–2050.\nNothnick WB, Curry TE, Vernon MW. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol. 1994;31(2-3):151–162.\nVlahos NF, Gregoriou O, Deliveliotou A, et al. Effect of pentoxifylline on vascular endothelial growth factor C and flk-1 expression on endometrial implants in the rat endometriosis model. Fertil Steril. 2010;93(4):1316–1323.\nTirado-Gonzâlez I, Barrientos G, Tariverdian N, et al. Endometriosis research: animal models for the study of a complex disease. J Reprod Immunol. 2010;86(2):141–141.\nNovella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009;24(5):1025–1035.\nNap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004;89(3):1089–1095.\nvan Kaam KJ, Schouten JP, Nap AW, Dunselman GA, Groothuis PG. Fibromuscular differentiation in deeply infiltrating endometriosis is a reaction of resident fibroblasts to the presence of ectopic endometrium. Hum Reprod. 2008;23(12):2692–2700.\nLaschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update. 2007;13(4):331–342.\nMay K, Becker CM. Endometriosis and angiogenesis. Minerva Ginecol. 2008;60(3):245–254.\nKamran MZ, Gude RP. Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother. 2013;67(5):399–405. doi:10.1016/j.biopha.2013.03.020.\nWu MY, Ho HN. The role of cytokines in endometriosis. Am J Reprod Immunol. 2003;49(5):285–296.\nPodgaec S, Dias Junior JA, Chapron C, Oliveira RM, Baracat EC, Abrão MS. Th1 and Th2 immune responses related to pelvic endometriosis. Rev Assoc Med Bras. 2010;56(1):92–98.\nHassan I, Dorjay K, Anwar P. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014;5(4):510–516.\nTariverdian N, Theoharides TC, Siedentopf F, et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 2007;29(2):193–210.\nLopera DE, Naranjo TW, Hidalgo JM, et al. Pentoxifylline immunomodulation in the treatment of experimental chronic pulmonary paracoccidioidomycosis. Fibrogenesis Tissue Repair. 2015;8:10.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nPerelló, M., González-Foruria, I., Castillo, P. et al. Oral Administration of Pentoxifylline Reduces Endometriosis-Like Lesions in a Nude Mouse Model. Reprod. Sci. 24, 911–918 (2017). https://doi.org/10.1177/1933719116673198\nPublished:\nIssue date:\nDOI: https://doi.org/10.1177/1933719116673198","source_license":"CC0","license_restricted":false}